Fig. 6

Insulin alleviated colitis through the LCA-Tgr5 pathway. A–D Mice were given water supplemented with 2.5% DSS and were treated with 100 μL of bile acid suspension (5 mg LCA) or vehicle control (VE) via the rectum on days 3, 5, and 7. B Changes in body weight were monitored daily after DSS administration. C DAI scores and D colon length in all the groups. E–H GW4064 was orally administered at a dose of 10 mg/kg twice with a 12-h interval between doses. Then, 2.5% DSS was given to the mice, and insulin and LCA were administered. F Body weight, G DAI scores and H colon length of the mice in the control, GW4064, GW4064 + insulin, and GW4064 + LCA groups. I–L Mice were administered methylated siRNA targeting Tgr5 by intraperitoneal injection (1 OD/mouse) on days -3, 0 and 2 of the experiment. Three days after the first administration of siRNAs, 2.5% DSS was administered to the mice, and then, the mice were treated with insulin and LCA. J Body weight, K DAI scores and L colon length in all the groups. The data represent the mean ± SD. NS, not significant; *P < 0.05; **P < 0.01; ***P < 0.001